| Rank | Stock | Price | Rev. Gr. | Dist. 52WH | Perf. 20D |
|---|---|---|---|---|---|
| WKN | Symbol | EPS Growth | Rel. Strength | |||
| 1 | Verisk Analytics | 278.09 $ | 26.37 % | 9.32 % | -3.45 % |
| A0YA2M | VRSK | 88.86 % | 86 | |||
| 2 | Palomar Holdings | 130.13 $ | 40.22 % | 9.49 % | -0.24 % |
| A2PHB6 | PLMR | 49.48 % | 96 | |||
| 3 | HCI Group | 137.14 $ | 49.16 % | 9.70 % | -1.56 % |
| A1W02H | HCI | 199.39 % | 85 | |||
| 4 | Progressive | 259.68 $ | 22.67 % | 11.37 % | -6.44 % |
| 865496 | PGR | 198.70 % | 88 | |||
| 5 | Universal Technical Institute | 26.47 $ | 20.63 % | 13.39 % | -1.64 % |
| 590097 | UTI | 533.33 % | 96 | |||
| 6 | Halozyme Therapeutics | 56.53 $ | 21.35 % | 14.34 % | -7.15 % |
| A0DLHS | HALO | 60.73 % | 92 | |||
| 7 | Insulet | 246.49 $ | 27.42 % | 14.84 % | -0.76 % |
| A0MQX8 | PODD | 250.00 % | 92 | |||
| 8 | Interdigital | 192.19 $ | 28.53 % | 17.15 % | -9.55 % |
| A0MWY3 | IDCC | 41.33 % | 98 | |||
| 9 | Tradeweb Markets | 122.34 $ | 29.44 % | 19.86 % | -8.22 % |
| TW | 20.69 % | 84 | |||
| 10 | Catalyst Pharmaceuticals | 20.86 $ | 32.17 % | 20.27 % | -1.62 % |
| A0LCUL | CPRX | 111.86 % | 90 |
| Halozyme Therapeutics | |
|---|---|
| 5-year chart | |
| Mkt. cap. | 9.46 B USD |
| P/S 24 | 9.76 |
| P/S 25 | 7.13 |
| P/E 24 | 23.46 |
| P/E 25 | 12.25 |
Cash flow instead of research risk: Thanks to a unique licensing model, Halozyme benefits from the successes of pharmaceutical giants without having to bear the billion-dollar risks of its own clinical trials. Growth at bargain prices: Despite a strong moat in the field of subcutaneous injections,...
